Somewhat Favorable News Coverage Somewhat Unlikely to Affect Dermira (DERM) Share Price
Press coverage about Dermira (NASDAQ:DERM) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dermira earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.1451590624818 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Dermira, Inc. (DERM) Stock Rating Reaffirmed by Needham & Company LLC (americanbankingnews.com)
- Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : September 15, 2017 (finance.yahoo.com)
- Axillary Hyperhidrosis – Diseases & Therapeutic Pipeline Review, H2 2017 (medgadget.com)
- BRIEF-New CIMZIA findings presented at European Academy Of Dermatology And Venereology (EADV) Congress (reuters.com)
- Dermira : Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients (4-traders.com)
Dermira (DERM) opened at 26.29 on Monday. The stock’s 50 day moving average is $24.55 and its 200-day moving average is $29.61. Dermira has a 12 month low of $21.35 and a 12 month high of $38.75. The firm’s market capitalization is $1.09 billion.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.04). The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.00 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. Equities analysts anticipate that Dermira will post ($4.20) earnings per share for the current fiscal year.
Several analysts have weighed in on DERM shares. Zacks Investment Research cut shares of Dermira from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Mizuho reaffirmed a “buy” rating and set a $43.00 price objective (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. BidaskClub cut shares of Dermira from a “buy” rating to a “hold” rating in a research note on Monday, July 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price objective on shares of Dermira in a research note on Tuesday, July 18th. Finally, Cantor Fitzgerald started coverage on shares of Dermira in a research note on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price objective on the stock. Four analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $44.40.
In other Dermira news, Director Fred B. Craves bought 30,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The shares were acquired at an average cost of $23.03 per share, for a total transaction of $690,900.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eugene A. Bauer sold 2,500 shares of Dermira stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $30.01, for a total transaction of $75,025.00. The disclosure for this sale can be found here. Insiders have sold a total of 11,700 shares of company stock worth $337,537 over the last ninety days. 13.30% of the stock is currently owned by insiders.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.